JP2018537975A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537975A5 JP2018537975A5 JP2018527739A JP2018527739A JP2018537975A5 JP 2018537975 A5 JP2018537975 A5 JP 2018537975A5 JP 2018527739 A JP2018527739 A JP 2018527739A JP 2018527739 A JP2018527739 A JP 2018527739A JP 2018537975 A5 JP2018537975 A5 JP 2018537975A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260854P | 2015-11-30 | 2015-11-30 | |
| US62/260,854 | 2015-11-30 | ||
| US201662289744P | 2016-02-01 | 2016-02-01 | |
| US201662289727P | 2016-02-01 | 2016-02-01 | |
| US62/289,727 | 2016-02-01 | ||
| US62/289,744 | 2016-02-01 | ||
| US201662409105P | 2016-10-17 | 2016-10-17 | |
| US62/409,105 | 2016-10-17 | ||
| PCT/IB2016/057017 WO2017093844A1 (en) | 2015-11-30 | 2016-11-22 | Site specific her2 antibody drug conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537975A JP2018537975A (ja) | 2018-12-27 |
| JP2018537975A5 true JP2018537975A5 (enExample) | 2020-01-16 |
| JP6979950B2 JP6979950B2 (ja) | 2021-12-15 |
Family
ID=57485830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018527739A Expired - Fee Related JP6979950B2 (ja) | 2015-11-30 | 2016-11-22 | 部位特異的ｈｅｒ２抗体薬物コンジュゲート |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10689458B2 (enExample) |
| EP (1) | EP3383918A1 (enExample) |
| JP (1) | JP6979950B2 (enExample) |
| KR (2) | KR102208317B1 (enExample) |
| CN (1) | CN108473591B (enExample) |
| AU (1) | AU2016363373A1 (enExample) |
| BR (1) | BR112018010102A2 (enExample) |
| CA (1) | CA2949032A1 (enExample) |
| CO (1) | CO2018005433A2 (enExample) |
| IL (1) | IL259651B2 (enExample) |
| MX (1) | MX2018006582A (enExample) |
| PH (1) | PH12018501043A1 (enExample) |
| RU (1) | RU2745565C2 (enExample) |
| SG (2) | SG10202005102YA (enExample) |
| TW (3) | TWI778491B (enExample) |
| WO (1) | WO2017093844A1 (enExample) |
| ZA (1) | ZA201803205B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3539982B1 (en) | 2011-12-23 | 2025-02-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| EP3525828B1 (en) | 2016-10-17 | 2024-12-25 | Pfizer Inc. | Anti-edb antibodies and antibody-drug conjugates |
| CA3177215A1 (en) | 2017-09-19 | 2019-03-28 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| US12172986B2 (en) | 2018-06-01 | 2024-12-24 | Eisai R&D Management Co., Ltd | Splicing modulator antibody-drug conjugates and methods of use |
| WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
| CN114901308A (zh) * | 2019-10-29 | 2022-08-12 | 石药集团巨石生物制药有限公司 | 使用抗her2抗体药物缀合物治疗癌症的组合物和方法 |
| US20230061858A1 (en) | 2019-12-20 | 2023-03-02 | Pfizer Inc. | Treatment with site specific her2 antibody-drug conjugates |
| CN115052632B (zh) * | 2020-01-15 | 2025-01-14 | 北京海步医药科技有限公司 | 靶向多肽-药物缀合物及其用途 |
| WO2022029591A1 (en) | 2020-08-04 | 2022-02-10 | Pfizer Inc. | Treatment with site specific her2 antibody-drug conjugates |
| CN112202628B (zh) * | 2020-09-08 | 2022-09-02 | 杭州涂鸦信息技术有限公司 | 一种WiFi模块串口协议自动化测试系统及方法 |
| CN112285361B (zh) * | 2020-09-27 | 2023-12-05 | 中国人民解放军空军军医大学 | 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂 |
| WO2022084560A1 (en) | 2020-10-25 | 2022-04-28 | Araris Biotech Ag | Means and methods for producing antibody-linker conjugates |
| AU2022222937A1 (en) * | 2021-02-18 | 2023-08-17 | Remegen Co., Ltd. | Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancer |
| JP2024538749A (ja) * | 2021-10-10 | 2024-10-23 | エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド | 抗ｐｄ－ｌ１／ｉｌ－１０融合タンパク質を用いて疾患を処置する方法 |
| EP4422695A1 (en) * | 2021-10-25 | 2024-09-04 | Araris Biotech AG | Methods for producing antibody-linker conjugates |
| KR20240135654A (ko) * | 2022-01-26 | 2024-09-11 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 항-her2/trop2 항체 및 이의 용도 |
| WO2024162772A1 (ko) * | 2023-02-01 | 2024-08-08 | 주식회사 에이티지씨 | 생체 내 지속성이 증가된 생리활성물질의 결합체 |
| WO2026025013A2 (en) | 2024-07-26 | 2026-01-29 | Pfizer Inc. | Combination therapy using cdk4 inhibitors for cancer treatments |
| WO2026093993A1 (en) | 2024-11-01 | 2026-05-07 | Janssen Biotech, Inc. | Methods and systems for enhanced multispecific metabolic and cellular targeting |
| CN120738196B (zh) * | 2025-09-03 | 2025-12-16 | 浙江博锐生物制药有限公司 | 编码抗her2抗体的核酸分子及其应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| GB9116610D0 (en) | 1991-08-01 | 1991-09-18 | Danbiosyst Uk | Preparation of microparticles |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| CA2364484A1 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| AU2001257577A1 (en) | 2000-02-28 | 2001-09-03 | Shearwater Corporation | Water-soluble polymer conjugates of artelinic acid |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| EP3434275A1 (en) | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Assay for cancer cells based on the use of auristatin conjugates with antibodies |
| MXPA06014065A (es) | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| HRP20141111T1 (hr) | 2004-07-22 | 2015-01-02 | Genentech, Inc. | Sastav her2-protutijela |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| EP1853294A4 (en) | 2005-03-03 | 2010-01-27 | Covx Technologies Ireland Ltd | ANTIANGIOGENIC COMPOUNDS |
| AU2006294554B2 (en) | 2005-09-26 | 2013-03-21 | E. R. Squibb & Sons, L.L.C. | Antibody-drug conjugates and methods of use |
| JPWO2008032833A1 (ja) | 2006-09-14 | 2010-01-28 | 株式会社医学生物学研究所 | Ａｄｃｃ活性を増強させた抗体及びその製造方法 |
| US20090098115A1 (en) * | 2006-10-20 | 2009-04-16 | Lisa Michele Crocker | Cell lines and animal models of HER2 expressing tumors |
| AU2008312457B2 (en) | 2007-10-19 | 2014-04-17 | Genentech, Inc. | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates |
| ES2613963T3 (es) | 2008-01-18 | 2017-05-29 | Medimmune, Llc | Anticuerpos manipulados con cisteína para conjugación específica de sitio |
| PT2247620T (pt) | 2008-01-31 | 2016-08-23 | Genentech Inc | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização |
| CA2766405A1 (en) | 2009-06-22 | 2011-01-13 | Medimmune, Llc | Engineered fc regions for site-specific conjugation |
| SG185428A1 (en) | 2010-06-08 | 2012-12-28 | Genentech Inc | Cysteine engineered antibodies and conjugates |
| SG187908A1 (en) | 2010-08-20 | 2013-03-28 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| CA2930801C (en) | 2010-11-05 | 2019-05-28 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| WO2012075581A1 (en) | 2010-12-06 | 2012-06-14 | Ym Biosciences Inc. | Antibodies selective for cells presenting erbb2 at high density |
| US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| US8871908B2 (en) | 2011-11-11 | 2014-10-28 | Rinat Neuroscience Corp. | Antibodies specific for Trop-2 and their uses |
| TWI589592B (zh) * | 2011-11-17 | 2017-07-01 | 輝瑞股份有限公司 | 胞毒性肽類以及其抗體藥物共軛體 |
| EP3539982B1 (en) | 2011-12-23 | 2025-02-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| WO2013165690A1 (en) | 2012-04-30 | 2013-11-07 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| AU2013263002C1 (en) | 2012-05-15 | 2018-05-31 | Seagen Inc. | Self-stabilizing linker conjugates |
| IN2015DN01361A (enExample) | 2012-08-02 | 2015-07-03 | Jn Biosciences Llc | |
| WO2014022846A1 (en) | 2012-08-03 | 2014-02-06 | Board Of Regents Of The University Of Nebraska | Cancer biomarkers and methods of use thereof |
| AU2013328621B2 (en) | 2012-10-12 | 2016-12-01 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-HER2 antibody conjugates |
| BR112015008251B1 (pt) | 2012-10-12 | 2023-09-26 | Medimmune Limited | Pirrolobenzodiazepinas, conjugados destas, composição e composição farmacêutica compreendendo os conjugados, uso dos conjugados para o tratamento de uma doença proliferativa e método para preparar os conjugados |
| HK1214161A1 (zh) | 2012-11-07 | 2016-07-22 | 辉瑞公司 | 抗IL-13受体α2抗体和抗体-药物缀合物 |
| CA2900755C (en) * | 2013-02-08 | 2021-07-20 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
| AU2014244245C1 (en) | 2013-03-13 | 2018-04-19 | Genentech, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| EP3018143B1 (en) | 2013-07-03 | 2019-05-29 | Seoul National University R&DB Foundation | Chicken antibody transformed into cysteine and site-specific conjugation using same |
| JP6993084B2 (ja) | 2013-08-12 | 2022-02-03 | ジェネンテック， インコーポレイテッド | １－（クロロメチル）－２，３－ジヒドロ－１ｈ－ベンゾ［ｅ］インドール二量体抗体 － 薬物コンジュゲート化合物、並びに使用及び処置の方法 |
| WO2015038426A1 (en) | 2013-09-13 | 2015-03-19 | Asana Biosciences, Llc | Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof |
| US9239324B2 (en) | 2013-12-06 | 2016-01-19 | Gang Chen | Antibody-binding protein-drug conjugate and methods of use |
| CA2934617A1 (en) | 2013-12-23 | 2015-07-02 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with kinesin spindle protein (ksp) |
| CA2937731C (en) | 2014-01-27 | 2019-09-24 | Pfizer Inc. | Bifunctional cytotoxic agents |
| SMT202500020T1 (it) * | 2014-02-28 | 2025-03-12 | Merus Nv | Anticorpo che lega erbb-2 ed erbb-3 |
| SG11201608192SA (en) | 2014-04-11 | 2016-10-28 | Medimmune Llc | Bispecific her2 antibodies |
| KR102486180B1 (ko) * | 2014-06-06 | 2023-01-11 | 레드우드 바이오사이언스 인코포레이티드 | 항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법 |
| WO2016151432A1 (en) | 2015-03-20 | 2016-09-29 | Pfizer Inc. | Bifunctional cytotoxic agents containing the cti pharmacophore |
| TWI703160B (zh) | 2015-11-30 | 2020-09-01 | 美商輝瑞股份有限公司 | 用於部位專一性接合之抗體和抗體片段 |
-
2016
- 2016-11-21 US US15/356,750 patent/US10689458B2/en active Active
- 2016-11-21 CA CA2949032A patent/CA2949032A1/en not_active Abandoned
- 2016-11-21 TW TW110100847A patent/TWI778491B/zh not_active IP Right Cessation
- 2016-11-21 TW TW108126399A patent/TWI727380B/zh not_active IP Right Cessation
- 2016-11-21 TW TW105138129A patent/TWI726942B/zh not_active IP Right Cessation
- 2016-11-22 KR KR1020187018244A patent/KR102208317B1/ko not_active Expired - Fee Related
- 2016-11-22 CN CN201680072749.4A patent/CN108473591B/zh not_active Expired - Fee Related
- 2016-11-22 SG SG10202005102YA patent/SG10202005102YA/en unknown
- 2016-11-22 SG SG11201803676PA patent/SG11201803676PA/en unknown
- 2016-11-22 BR BR112018010102-8A patent/BR112018010102A2/pt not_active IP Right Cessation
- 2016-11-22 EP EP16806285.9A patent/EP3383918A1/en not_active Withdrawn
- 2016-11-22 RU RU2018119683A patent/RU2745565C2/ru active
- 2016-11-22 MX MX2018006582A patent/MX2018006582A/es unknown
- 2016-11-22 KR KR1020207030005A patent/KR102312149B1/ko not_active Expired - Fee Related
- 2016-11-22 JP JP2018527739A patent/JP6979950B2/ja not_active Expired - Fee Related
- 2016-11-22 WO PCT/IB2016/057017 patent/WO2017093844A1/en not_active Ceased
- 2016-11-22 AU AU2016363373A patent/AU2016363373A1/en not_active Abandoned
-
2018
- 2018-05-15 ZA ZA2018/03205A patent/ZA201803205B/en unknown
- 2018-05-16 PH PH12018501043A patent/PH12018501043A1/en unknown
- 2018-05-24 CO CONC2018/0005433A patent/CO2018005433A2/es unknown
- 2018-05-28 IL IL259651A patent/IL259651B2/en unknown
-
2020
- 2020-06-03 US US16/891,460 patent/US20200377615A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018119683A (ru) | Сайт-специфические конъюгаты антитела к her2 и лекарственного средства | |
| TWI865337B (zh) | 抗體-藥物結合物之有效的製造方法 | |
| US12497465B2 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| TWI906070B (zh) | 抗體-藥物結合物之用途 | |
| AU2015205588B2 (en) | Duocarmycin ADCs for use in treatment of endometrial cancer | |
| JP2019532056A5 (enExample) | ||
| JP2015534577A5 (enExample) | ||
| JP2016502504A5 (enExample) | ||
| FI3283521T3 (fi) | Lääkekonjugaatteja käsittäen vasta-aineita claudiinia 18.2 vastaan | |
| JP2017514905A5 (enExample) | ||
| JP2021519076A5 (enExample) | ||
| JP2016505513A5 (enExample) | ||
| JP2012522512A5 (enExample) | ||
| JP2023545096A5 (enExample) | ||
| CN106999606A (zh) | 抗体药物偶联物 | |
| TW202537643A (zh) | 抗體-藥物結合物之用途 | |
| EP4294455A1 (en) | Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancer | |
| JP2016540826A5 (enExample) | ||
| JP2025517356A5 (enExample) | ||
| US20260139074A1 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| JP2020507569A5 (enExample) | ||
| JP2025540063A (ja) | 抗体－薬物コンジュゲートおよびｄｎｍｔ阻害剤の併用 | |
| BR122024023393A2 (pt) | Uso de um conjugado de anticorpo-fármaco, composição farmacêutica, e, combinação farmacêutica | |
| HK40130006A (zh) | 通过施用抗her2抗体-药物缀合物治疗her2突变的癌 | |
| TW202615105A (zh) | 抗體-藥物結合物之用途 |